Search Results - "Newstat, B."

5050 POSTER Lapatinib (L) in Combination With Paclitaxel (P) is an Effective and Tolerable Treatment in HER2-overexpressing Metastatic Breast Cancer (MBC) Patients by Guan, Z, Xu, B, DeSilvio, M, Newstat, B, Moore, Y, Makhson, A

Get full text

5082 Lapatinib (L) plus capecitabine (C) in HER2+ metastatic breast cancer (MBC): exploratory analyses by prior therapy by Crown, J, Casey, M.A, Cameron, D, Newstat, B, Stein, S.H

Get full text

5052 An open-label, single arm study of lapatinib and capecitabine in Chinese women with advanced or metastatic breast cancer (MBC) by Xu, B, Jiang, Z, Chua, D, Shao, Z, Luo, R, Wang, X, Newstat, B, Chi, H, Chen, G, Wang, L

Get full text

2096 ORAL Lapatinib (L) plus Capecitabine (C) in HER2+ advanced breast cancer (ABC): report of updated efficacy and gene-array data by Crown, J, Cameron, D, Martin, A.M, Newstat, B, Pienkowski, T, Jagiello-Gruszfeld, A, Kaufman, B, Casey, M.A, Stein, S, Geyer, C

Get full text

Abstract P3-14-24: Overall Survival Benefit Observed with Lapatinib (L) Plus Paclitaxel (P) as First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer (MBC) by Guan, Z-z, Xu, B-h, Arpornwirat, W, Tong, Z-s, Lorvidhaya, V, Wang, L, Newstat, B, DeSilvio, M, Moore, Y, Shen, Z-Z.

“…Background: Lapatinib (L) is a potent, oral selective, reversible, inhibitor of EGFR (ErbB1) and HER2 (ErbB2) receptor tyrosine kinases. EGF104535 is a phase…”
Get full text

Hyperbilirubinemia in Lapatinib Treated Patients Is Associated with Gilbert's Syndrome UGT1A1 Polymorphism by Spraggs, C., Budde, L., Briley, L., Bing, N., Newstat, B., Rappold, E., Mooser, V., Cardon, L., Stein, S.

“…Background: Lapatinib, an oral EGFR/HER2 tyrosine kinase inhibitor, is approved in combination with capecitabine for the treatment of patients with advanced or…”
Get full text

Frequency of PIK 3CA Mutations in Chinese HER2+ Metastatic Breast Cancer Patients and Association with Clinical Benefit to Lapatinib and Capecitabine Treatment by Xu, B., Zefei, J., Chua, D., Shao, Z., Luo, R., Wang, X., Yuan, P., Newstat, B., Liu, Y., Gagnon, R., Chi, H., Martin, A., Stein, S., Wang, L.

“…Background: Activating mutations in PIK3CA are frequent in breast cancer (Campbell et al. Cancer Res 2004;64:7678-7681). Previous analyses suggest that the…”
Get full text

Diarrhea events in cancer patients (pts) treated with lapatinib by Koehler, M., Chan, S., Newstat, B. O., Preston, A., Burris, H. A.

“…Abstract only 9125 Introduction: Lapatinib (L) is an oral dual ErbB1/ErbB2 tyrosine kinase inhibitor administered to > 5,000 pts in clinical trials. Low grade…”
Get full text

Correlation of HER2 gene amplification, HER2 and EGFR expression (protein and mRNA) with lapatinib efficacy in women with metastatic breast cancer by Press, M. F., Finn, R. S., Di Leo, A., Cameron, D. A., Geyer, C. E., Martin, A., Newstat, B., Gagnon, R., Arbushites, M., Koehler, M.

“…Abstract only…”
Get full text

Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data by Geyer, C. E., Martin, A., Newstat, B., Casey, M. A., Berger, M. S., Oliva, C. R., Rubin, S. D., Stein, S., Cameron, D.

“…Abstract only 1035 Background: EGF100151 demonstrated L+C improved TTP relative to C alone in women with HER2 positive, trastuzumab- exposed ABC (Geyer,…”
Get full text